Saltar al contenido
Black Friday — 30% OFFEnvío gratis en pedidos desde 99 €
  1. Inicio
  2. Recuperación y regeneración
  3. Livagen, 20mg
Recuperación

Livagen, 20mg

Livagen is a synthetic bioregulatory peptide being studied for its role in regulating DNA structure and gene expression.

Presentación: Livagen, 20mg.

Envase ilustrativo generado con IA.

El precio original era: 62,95 €.El precio actual es: 44,07 €.

No disponible actualmente en España

Consulta a un asesor
Un asesor se pone en contacto contigo y la farmacia asociada comprueba si es posible continuar y cómo. Puede ser necesaria una receta válida o una evaluación a través de un servicio de telemedicina autorizado.
  • Farmacia asociada
  • Atención personalizada
  • Entrega discreta
  • Presentación
    Livagen, 20mg

Envío y entrega

  • Envío habitual en 24 horas tras confirmarse el pago.
  • USPS Regular Shipping · 11,95 € · Aprox. 3–5 días laborables
  • FedEx 2 Days Delivery · 28,99 € · Aprox. 2 días laborables
  • FedEx Overnight Delivery · 40,99 € · Aprox. 1 día laborable

Solo para investigación de laboratorio.

No apto para uso humano o veterinario.

Composición y detalles del producto

Descripción

Livagen is a synthetic bioregulatory peptide being studied for its role in regulating DNA structure and gene expression. Research interest centers on its proposed capacity to promote chromatin decondensation, with effects most extensively studied in lymphocyte models alongside investigations into immune system modulation across cardiac, gastrointestinal, and neural tissue models.

Research applications include chromatin structure research, immune signalling pathway studies, and nociceptive pathway investigation.

  • High Purity – 99% Purity Guaranteed
  • Independently Lab Tested
  • Research Grade Quality
  • For Laboratory Research Use Only

Propiedades

Chemical Formula C18H31N5O9
Synonyms SCHEMBL5967826
Molar Mass 461.5 g/mol
CAS Number 195875-84-4
PubChem CID 87919683
Total Compound Content 20mg per vial
Shelf Life 36 months

Investigación

Livagen is studied for its proposed role in promoting chromatin decondensation, a mechanism that may enhance accessibility and expression of genes associated with cellular homeostasis. Its effects have been most extensively characterised in lymphocyte cell models, with additional investigations examining immune system modulation and signalling across cardiac, gastrointestinal, and neural tissue model systems. Additional research has examined Livagen’s influence on nociceptive signalling pathways, positioning it within bioregulatory peptide research spanning chromatin biology, immune regulation, and pain pathway investigation. Independently third-party HPLC-tested; COA available per batch.

FAQ

What methods are used to study Livagen’s proposed effect on chromatin decondensation in lymphocyte models?

Chromatin accessibility assays (such as ATAC-seq or micrococcal nuclease digestion-based methods) and microscopy-based heterochromatin/euchromatin ratio quantification are standard approaches for studying Livagen’s reported effects on chromatin structure in lymphocyte cell models. These methods allow researchers to compare chromatin organisation state before and after compound exposure, often paired with downstream gene expression analysis (RNA-seq or targeted qPCR) to connect any observed chromatin structural change to functional transcriptional outcomes.

How is Livagen’s immune modulation studied across different tissue model systems?

Tissue-specific immune signalling research with Livagen typically uses isolated immune cell populations relevant to each tissue context — cardiac-resident immune cells, gut-associated lymphoid tissue cells, and neural-immune interface cell populations (such as microglia) — measuring cytokine profiles and immune cell activation markers following compound exposure in each tissue-specific model. Comparative analysis across these tissue contexts allows researchers to determine whether Livagen’s immune-modulatory mechanism is tissue-general or exhibits tissue-specific variation.

What experimental approaches investigate Livagen’s reported influence on nociceptive signaling pathways?

Rodent behavioral nociception models (such as von Frey filament mechanical sensitivity testing or thermal withdrawal latency assays) combined with molecular analysis of pain-signalling pathway components (such as TRPV1 channel expression or neuroinflammatory markers in dorsal root ganglia) are used to study Livagen’s relevance to nociceptive pathway research. These combined behavioral and molecular endpoints allow researchers to connect any functional change in pain-related behavior to underlying signalling pathway modulation.